Proposed LCD DL40199: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis — CGS
Policy LCD-DL40199 · Gastroenterology
New LCD may affect billing for liver disease biomarker testing.